Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Benjamin M. Larimer
University of Alabama at Birmingham, Department: Radiation Diagnostic/oncology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cytosite Biopharma Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The outcome of the research is of significant business interest to the entity and therefore the financial interest is likely to change based on the result.
Quantitative PET Imaging for Oncologic Immune Response Prediction
Project Narrative Immune checkpoint inhibitors activate the immune system to recognize and attack cancer cells, and have markedly advanced treatment options for patients with a broad variety of cancers. However, standard imaging methods are often not useful in response assessment of immune modulators due to a lack of change in tumor size or metabolic activity with an immune cell infiltrate. To address this unmet clinical and research need, a novel PET imaging approach will be utilized to measure T cell activation within a tumor as a new imaging paradigm for tumoral response evaluation to immune modulators.
Filed on August 08, 2019.
Tell us what you know about Benjamin M. Larimer's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Benjamin M. Larimer filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Benjamin M. Larimer | University of Alabama at Birmingham | Conflict of Interest | Cytosite Biopharma Inc. | $60,000 - $79,999 |
| Benjamin Larimer | Massachusetts General Hospital | Conflict of Interest | CytoSite BioPharma, Inc. | $10,000 - $19,999 |
| Benjamin Larimer | Massachusetts General Hospital | Conflict of Interest | CytoSite BioPharma, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.